These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 15184867)
1. Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Foster CS; Falconer A; Dodson AR; Norman AR; Dennis N; Fletcher A; Southgate C; Dowe A; Dearnaley D; Jhavar S; Eeles R; Feber A; Cooper CS Oncogene; 2004 Aug; 23(35):5871-9. PubMed ID: 15184867 [TBL] [Abstract][Full Text] [Related]
2. Nuclear overexpression of the E2F3 transcription factor in human lung cancer. Cooper CS; Nicholson AG; Foster C; Dodson A; Edwards S; Fletcher A; Roe T; Clark J; Joshi A; Norman A; Feber A; Lin D; Gao Y; Shipley J; Cheng SJ Lung Cancer; 2006 Nov; 54(2):155-62. PubMed ID: 16938365 [TBL] [Abstract][Full Text] [Related]
3. Amplification and overexpression of E2F3 in human bladder cancer. Feber A; Clark J; Goodwin G; Dodson AR; Smith PH; Fletcher A; Edwards S; Flohr P; Falconer A; Roe T; Kovacs G; Dennis N; Fisher C; Wooster R; Huddart R; Foster CS; Cooper CS Oncogene; 2004 Feb; 23(8):1627-30. PubMed ID: 14716298 [TBL] [Abstract][Full Text] [Related]
4. E2F3 amplification and overexpression is associated with invasive tumor growth and rapid tumor cell proliferation in urinary bladder cancer. Oeggerli M; Tomovska S; Schraml P; Calvano-Forte D; Schafroth S; Simon R; Gasser T; Mihatsch MJ; Sauter G Oncogene; 2004 Jul; 23(33):5616-23. PubMed ID: 15122326 [TBL] [Abstract][Full Text] [Related]
5. HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected androgen-dependent and androgen-independent cancer. Montironi R; Mazzucchelli R; Barbisan F; Stramazzotti D; Santinelli A; Scarpelli M; Lòpez Beltran A Hum Pathol; 2006 Sep; 37(9):1137-44. PubMed ID: 16938518 [TBL] [Abstract][Full Text] [Related]
6. Activation of signal transducer and activator of transcription-5 in prostate cancer predicts early recurrence. Li H; Zhang Y; Glass A; Zellweger T; Gehan E; Bubendorf L; Gelmann EP; Nevalainen MT Clin Cancer Res; 2005 Aug; 11(16):5863-8. PubMed ID: 16115927 [TBL] [Abstract][Full Text] [Related]
7. Expression of sialylated MUC1 in prostate cancer: relationship to clinical stage and prognosis. Arai T; Fujita K; Fujime M; Irimura T Int J Urol; 2005 Jul; 12(7):654-61. PubMed ID: 16045558 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of immunohistochemical expression of the HER-2/neu oncoprotein in bone metastatic prostate cancer. Nishio Y; Yamada Y; Kokubo H; Nakamura K; Aoki S; Taki T; Honda N; Nakagawa A; Saga S; Hara K Urology; 2006 Jul; 68(1):110-5. PubMed ID: 16806433 [TBL] [Abstract][Full Text] [Related]
9. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues: implications for prostate carcinogenesis and progression of prostate cancer. Zhigang Z; Wenlv S Jpn J Clin Oncol; 2004 Jul; 34(7):414-9. PubMed ID: 15342669 [TBL] [Abstract][Full Text] [Related]
10. Distinct expression patterns of the transcription factor E2F-1 in relation to tumour growth parameters in common human carcinomas. Zacharatos P; Kotsinas A; Evangelou K; Karakaidos P; Vassiliou LV; Rezaei N; Kyroudi A; Kittas C; Patsouris E; Papavassiliou AG; Gorgoulis VG J Pathol; 2004 Jul; 203(3):744-53. PubMed ID: 15221933 [TBL] [Abstract][Full Text] [Related]
11. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Davis JN; Wojno KJ; Daignault S; Hofer MD; Kuefer R; Rubin MA; Day ML Cancer Res; 2006 Dec; 66(24):11897-906. PubMed ID: 17178887 [TBL] [Abstract][Full Text] [Related]
12. Increased expression of SIM2-s protein is a novel marker of aggressive prostate cancer. Halvorsen OJ; Rostad K; Øyan AM; Puntervoll H; Bø TH; Stordrange L; Olsen S; Haukaas SA; Hood L; Jonassen I; Kalland KH; Akslen LA Clin Cancer Res; 2007 Feb; 13(3):892-7. PubMed ID: 17289882 [TBL] [Abstract][Full Text] [Related]
13. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Murphy AJ; Hughes CA; Barrett C; Magee H; Loftus B; O'Leary JJ; Sheils O Cancer Res; 2007 Mar; 67(6):2893-8. PubMed ID: 17363613 [TBL] [Abstract][Full Text] [Related]
14. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade. Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706 [TBL] [Abstract][Full Text] [Related]
15. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. Diallo JS; Aldejmah A; Mouhim AF; Fahmy MA; Koumakpayi IH; Sircar K; Bégin LR; Mes-Masson AM; Saad F BJU Int; 2008 May; 101(10):1302-9. PubMed ID: 18294307 [TBL] [Abstract][Full Text] [Related]
16. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer. Wong WW; Schild SE; Vora SA; Halyard MY Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536 [TBL] [Abstract][Full Text] [Related]
17. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. Hansel DE; DeMarzo AM; Platz EA; Jadallah S; Hicks J; Epstein JI; Partin AW; Netto GJ J Urol; 2007 May; 177(5):1736-40. PubMed ID: 17437801 [TBL] [Abstract][Full Text] [Related]
18. Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. Banham AH; Boddy J; Launchbury R; Han C; Turley H; Malone PR; Harris AL; Fox SB Prostate; 2007 Jul; 67(10):1091-8. PubMed ID: 17477366 [TBL] [Abstract][Full Text] [Related]
19. E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer. Oeggerli M; Schraml P; Ruiz C; Bloch M; Novotny H; Mirlacher M; Sauter G; Simon R Oncogene; 2006 Oct; 25(49):6538-43. PubMed ID: 16953223 [TBL] [Abstract][Full Text] [Related]
20. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma. Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]